Abstract
No public abstract is available from the verified source records.
Jiahong Shi, Peihai Cao, Juan Bai, Yutiantian Lei, Mengdi Huang, Mingjun Si, Ruiying Wang, Tingting Lv, Rui Jia, Qiuyu Mu, Dingge Jiang, Yuzhu Hou, Shan Hong Huang
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study
10.1016/s2214-109x(24)00355-3 · 2024
Immunogenic cell death driven by radiation-impact on the tumor microenvironment
10.1007/978-3-030-38862-1_10 · 2020
Radiotherapy, immunity, and immune checkpoint inhibitors
10.1016/s1470-2045(24)00075-5 · 2024
Emerging evidence for adapting radiotherapy to immunotherapy
10.1038/s41571-023-00782-x · 2023
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations
10.1093/jnci/djad118 · 2023
Radiation with immunotherapy may be a double-edged sword-how can we learn from recent negative clinical trials?
10.1001/jamaoncol.2024.1527 · 2024
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer
10.1200/jco.2006.07.5937 · 2006
Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies
10.1016/j.bpg.2016.07.003 · 2016
Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
openalex
Confidence 95%
datacite
Confidence 0%
10.1038/s41598-025-06909-7 · 2025
Radiation-induced upregulation of FGL1 promotes esophageal squamous cell carcinoma metastasis via IMPDH1
10.1186/s12885-024-12313-7 · 2024
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
10.1038/s41590-019-0561-4 · 2020
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
10.1016/j.immuni.2014.10.019 · 2014
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
10.1186/s13045-020-00940-z · 2020
Dosimetric impact of esophagus motion in single fraction spine stereotactic body radiotherapy
10.1088/1361-6560/ab1c2b · 2019
Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery
10.1007/s00066-020-01603-1 · 2020
The multifunctional protein HMGB1: 50 years of discovery
10.1038/s41577-023-00894-6 · 2023
HMGB1 silencing in macrophages prevented their functional skewing and ameliorated EAM development: nuclear HMGB1 may be a checkpoint molecule of macrophage reprogramming
10.1016/j.intimp.2018.01.013 · 2018
HMGB1 coordinates SASP-related chromatin folding and RNA homeostasis on the path to senescence
10.15252/msb.20209760 · 2021
Nuclear HMGB1 is critical for CD8 T cell IFN-gamma production and anti-tumor immunity
10.1016/j.celrep.2024.114591 · 2024
O-GlcNAcylation enhances double-strand break repair, promotes cancer cell proliferation, and prevents therapy-induced senescence in irradiated tumors
10.1158/1541-7786.mcr-18-1025 · 2019
PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer
10.1038/s41467-024-51242-8 · 2024
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
2016
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
10.1186/s12929-020-00670-x · 2020
CXCR5(+) monocyte emigration impairs the radiation-induced antitumor immune response
10.1038/s41467-026-70858-6 · 2026
Radiotherapy and immunology
10.1084/jem.20232101 · 2024
Myeloid effector cells in cancer
10.1016/j.ccell.2024.11.002 · 2024
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes
10.1158/0008-5472.can-09-4672 · 2010
CCL2 (monocyte chemoattractant protein-1) and cancer
10.1016/j.semcancer.2003.10.009 · 2004
Chemokines and the immune response to cancer
10.1016/j.immuni.2021.01.012 · 2021
Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies
2025
Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy
10.1016/j.semcancer.2021.04.002 · 2022
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy
10.1172/jci.insight.130362 · 2020
Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy
10.1016/j.ijrobp.2014.08.008 · 2014
JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer
10.2217/fon-2018-0405 · 2019
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
10.1016/s1470-2045(24)00100-1 · 2024
Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study
10.1200/jco-25-00036 · 2025
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
10.1038/nature00858 · 2002
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
10.1038/nm1622 · 2007
High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair
10.1111/imr.12601 · 2017
The mechanism of HMGB1 secretion and release
10.1038/s12276-022-00736-w · 2022
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer
10.1038/s41467-021-22618-x · doi-reference
Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells
10.1016/j.celrep.2017.07.027 · doi-reference
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment
10.1158/0008-5472.can-11-1792 · doi-reference
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
10.1038/nature10138 · doi-reference
CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis
10.1186/s12943-020-01165-x · doi-reference
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
10.1136/gutjnl-2015-310514 · doi-reference
Elevated mast cell abundance is associated with enrichment of CCR2+ cytotoxic T cells and favorable prognosis in lung adenocarcinoma
10.1158/0008-5472.can-22-3140 · doi-reference
Cytoplasmic HMGB1 promotes the activation of JAK2-STAT3 signaling and PD-L1 expression in breast cancer
10.1186/s10020-025-01235-0 · doi-reference
The mechanism of HMGB1 secretion and release
10.1038/s12276-022-00736-w · doi-reference
High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair
10.1111/imr.12601 · doi-reference
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
10.1038/nm1622 · doi-reference
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
10.1038/nature00858 · doi-reference
Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study
10.1200/jco-25-00036 · doi-reference
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
10.1016/s1470-2045(24)00100-1 · doi-reference
JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer
10.2217/fon-2018-0405 · doi-reference
Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy
10.1016/j.ijrobp.2014.08.008 · doi-reference
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy
10.1172/jci.insight.130362 · doi-reference
Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy
10.1016/j.semcancer.2021.04.002 · doi-reference
Chemokines and the immune response to cancer
10.1016/j.immuni.2021.01.012 · doi-reference
CCL2 (monocyte chemoattractant protein-1) and cancer
10.1016/j.semcancer.2003.10.009 · doi-reference
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes
10.1158/0008-5472.can-09-4672 · doi-reference
Radiotherapy and immunology
10.1084/jem.20232101 · doi-reference
CXCR5(+) monocyte emigration impairs the radiation-induced antitumor immune response
10.1038/s41467-026-70858-6 · doi-reference
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
10.1186/s12929-020-00670-x · doi-reference
PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer
10.1038/s41467-024-51242-8 · doi-reference
O-GlcNAcylation enhances double-strand break repair, promotes cancer cell proliferation, and prevents therapy-induced senescence in irradiated tumors
10.1158/1541-7786.mcr-18-1025 · doi-reference
Nuclear HMGB1 is critical for CD8 T cell IFN-gamma production and anti-tumor immunity
10.1016/j.celrep.2024.114591 · doi-reference
HMGB1 coordinates SASP-related chromatin folding and RNA homeostasis on the path to senescence
10.15252/msb.20209760 · doi-reference
HMGB1 silencing in macrophages prevented their functional skewing and ameliorated EAM development: nuclear HMGB1 may be a checkpoint molecule of macrophage reprogramming
10.1016/j.intimp.2018.01.013 · doi-reference
The multifunctional protein HMGB1: 50 years of discovery
10.1038/s41577-023-00894-6 · doi-reference
Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery
10.1007/s00066-020-01603-1 · doi-reference
Dosimetric impact of esophagus motion in single fraction spine stereotactic body radiotherapy
10.1088/1361-6560/ab1c2b · doi-reference
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
10.1186/s13045-020-00940-z · doi-reference
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
10.1016/j.immuni.2014.10.019 · doi-reference
Myeloid effector cells in cancer
10.1016/j.ccell.2024.11.002 · doi-reference
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
10.1038/s41590-019-0561-4 · doi-reference
Radiation-induced upregulation of FGL1 promotes esophageal squamous cell carcinoma metastasis via IMPDH1
10.1186/s12885-024-12313-7 · doi-reference
Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma
10.1038/s41598-025-06909-7 · doi-reference
Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies
10.1016/j.bpg.2016.07.003 · doi-reference
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer
10.1200/jco.2006.07.5937 · doi-reference